Kinarus Therapeutics Phase 2 KINFAST Covid-19 Clinical Trial Progress Update

Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, provided an update today on progress of its Phase 2 KINFAST trial of KIN001 in Covid-19.